Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 3/20 | 0.71 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.71 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.71 |
| ▸ | HMGCR | P04035 | 8/20 | 0.69 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.69 |
| ▸ | ESR1 | P03372 | 1/20 | 0.69 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.69 |
| ▸ | PDE4A | P27815 | 1/20 | 0.69 |
| ▸ | RXRA | P19793 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.60 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.60 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | PGR | P06401 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | CCKAR | P32238 | 1/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.60 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5500466 | 1.00 | PDE4D (0.71) | PDE4DNR4A2NR1I2HMGCRTBXA2R | |
| SCHEMBL27616710 | 1.00 | PDE4D (0.71) | PDE4DNR4A2NR1I2HMGCRTBXA2R | |
| SCHEMBL5500469 | 1.00 | PDE4D (0.71) | PDE4DNR4A2NR1I2HMGCRTBXA2R | |
| SCHEMBL6242551 | 1.00 | PDE4D (0.71) | PDE4DNR4A2NR1I2HMGCRTBXA2R | |
| SCHEMBL10660040 | 1.00 | PDE4D (0.71) | PDE4DNR4A2NR1I2HMGCRTBXA2R | |
| SCHEMBL5535535 | 1.00 | PDE4D (0.71) | PDE4DNR4A2NR1I2HMGCRTBXA2R | |
| SCHEMBL27517669 | 0.99 | PDE4D (0.70) | PDE4DNR4A2NR1I2HMGCRTBXA2R | |
| SCHEMBL8322970 | 0.93 | PDE4D (0.61) | PDE4DNR4A2NR1I2HMGCRTBXA2R | |
| SCHEMBL8325578 | 0.91 | PDE4D (0.59) | PDE4DNR4A2NR1I2HMGCRTBXA2R | |
| SCHEMBL8323602 | 0.88 | HMGCR (0.66) | PDE4DNR4A2NR1I2HMGCRTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0304063-B1 | Quinoline type mevalonolactones | NISSAN CHEMICAL IND LTD (JP) | 1994-11-30 | — | — | EP | claimed |
| EP-0304063-A2 | Quinoline type mevalonolactones | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1989-02-22 | — | — | EP | claimed |
| US-7232915-B2 | Process for the synthesis of 1,3-diols | WARNER-LAMBERT COMPANY (US) | 2007-06-19 | — | — | US | disclosed |
| EP-1054860-B1 | PROCESS FOR THE SYNTHESIS OF 1,3-DIOLS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2007-04-25 | — | — | EP | disclosed |
| US-6962994-B2 | Process for the synthesis of 1,3-diols | WARNER-LAMBERT COMPANY, LLC (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050239884-A1 | Compositions comprising hmg-coa reductase inhibitor | MEYER ANDREAS | 2005-10-27 | — | — | US | disclosed |
| US-20050197500-A1 | Process for the synthesis of 1,3-diols | BOSCH ROBERT L (US) | 2005-09-08 | — | — | US | disclosed |
| EP-1536775-A1 | COMPOSITIONS COMPRISING HMG-COA REDUCTASE INHIBITOR | Novartis AG (CH) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004010980-A1 | COMPOSITIONS COMPRISING HMG-COA REDUCTASE INHIBITOR | NOVARTIS AG (CH) | 2004-02-05 | — | — | WO | disclosed |
| US-20040006231-A1 | Process for the synthesis of 1,3-diols | BOSCH ROBERT LEE (US) | 2004-01-08 | — | — | US | disclosed |
| US-20030203964-A1 | Process for producing medicaments which comprise HMG CoA reductase inhibitors | SCHUCKLER FRITZ (DE) | 2003-10-30 | — | — | US | disclosed |
| US-5856336-A | Quinoline type mevalonolactones | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1999-01-05 | — | — | US | disclosed |
| US-5854259-A | Quinoline type mevalonolactones | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1998-12-29 | — | — | US | disclosed |
| EP-0304063-B1 | Quinoline type mevalonolactones | NISSAN CHEMICAL IND LTD (JP) | 1994-11-30 | — | — | EP | disclosed |
| EP-0547000-A1 | Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor compound | SANDOZ LTD. (CH) | 1993-06-16 | — | — | EP | disclosed |
| US-5185328-A | Hydroxy-3-methylglutaryl/3-/ coenzyme A reductase inhibitors | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1993-02-09 | — | — | US | disclosed |
| US-5102888-A | QUINOLINE TYPE MEVALONOLACTONES USEFUL FOR TREATING HYPERLIPIDEMIA AND RELATED DISEASES | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| US-5011930-A | Antilipemic agents, anticoagulants | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1991-04-30 | — | — | US | disclosed |
| EP-0304063-A2 | Quinoline type mevalonolactones | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1989-02-22 | — | — | EP | disclosed |
| US-4761419-A | ANTILIPEMIC | WARNER-LAMBERT COMPANY (US) | 1988-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203964-A1 | Process for producing medicaments which comprise HMG CoA reductase inhibitors | HMGCR, CYP11A1, CYP46A1 | PDE4D 4577/4885NR4A2 3719/4885NR1I2 487/4885 |
| US-20050197500-A1 | Process for the synthesis of 1,3-diols | HSD17B7, HSD11B1, BCKDK | PDE4D 4263/4885NR4A2 2247/4885NR1I2 1651/4885 |
| US-20040006231-A1 | Process for the synthesis of 1,3-diols | HSD17B7, HSD11B1, BCKDK | PDE4D 4263/4885NR4A2 2247/4885NR1I2 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.